PD-L1 IHC 22C3 pharmDx can help identify urothelial carcinoma patients for treatment with KEYTRUDA
PD-L1 is a proven biomarker for patient response to KEYTRUDA in urothelial carcinoma
Urothelial carcinoma is the fifth most common cancer in the United States and there is an urgent need for new effective treatments for patients
For patients with advanced/metastatic urothelial carcinoma, the five-year survival rate is approximately 15%, and cancer-related mortality has not improved in the past 30 years
Anti-PD-1 therapies are a promising new treatment class for many cancer types–the KEYNOTE-052 clinical trial studied the efficacy of KEYTRUDA, an anti-PD-1 monotherapy, at first-line in patients with locally advanced or metastatic urothelial carcinoma who were ineligible for cisplatin-containing chemotherapy
IHC testing for PD-L1 expression levels enables identification of patients most likely to benefit from anti-PD-1 monotherapy
Trust the ONE companion diagnostic FDA-approved to determine PD-L1 expression in patients with urothelial carcinoma for treatment with KEYTRUDA
Proven in KEYNOTE-052 for PD-L1 results in urothelial carcinoma
PD-L1 IHC 22C3 pharmDx was the only IHC assay used to assess PD-L1 expression in the KEYNOTE-052 clinical trial
PD-L1 IHC 22C3 pharmDx offers the assurance of the only PD-L1 test FDA-approved as a companion diagnostic for KEYTRUDA
PD-L1 IHC 22C3 pharmDx Urothelial Carcinoma Interpretation ManualRefer to the Urothelial Carcinoma Interpretation Manual to review validated scoring guidelines that can help identify patients for treatment with KEYTRUDA
Online Atlas of Stains for Urothelial Carcinoma: PD‑L1 IHC 22C3 pharmDx Use the Online Atlas of Stains for Urothelial Carcinoma to increase your familiarity with PD-L1 staining in urothelial carcinoma specimens
PD-L1 testing with PD-L1 IHC 22C3 pharmDx should be an integral part of patient care from day ONE
Early PD-L1 testing can provide critical information for physicians managing urothelial carcinoma patients who are ineligible for cisplatin-containing chemotherapy
For patients ineligible for cisplatin-containing chemotherapy, there is a significant unmet need for treatment alternatives
Age- and disease-associated comorbidities of urothelial carcinoma patients, including renal dysfunction and poor performance status, affect treatment choices and eligibility for standard cisplatin-containing chemotherapy
In clinical practice, these comorbidities may be exacerbated by cisplatin-related toxicities
There is no standard of care for patients ineligible for standard cisplatin-containing chemotherapy
* See the KEYTRUDA product label for specific clinical circumstances guiding PD-L1 testing
KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
References:1. PD-L1 IHC 22C3 pharmDx [package insert]. Carpinteria, CA: Dako, Agilent Pathology Solutions; 2018.
2. Keytruda [package insert]. Kenilworth, NJ: Merck & Co., Inc.; 2018.
3. Gupta S, Gill D, Poole A, Agarwal N. Systemic immunotherapy for urothelial cancer: current trends and future directions. Cancers. 2017;9(15):1-14.
4. Bellmunt J, Mottet N, De Santis M. Urothelial carcinoma management in elderly or unfit patients. EJC Suppl. 2016;14(1):1-20.
5. Balar AV, Castellano D, O'Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study. Lancet. 2017;18(11):1483-1492.
6. Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer "unfit" for cisplatin-based chemotherapy. J Clin Oncol. 2011;29(17):2432-2438.
For countries outside of the United States, see the local KEYTRUDA product label for approved indications and expression cutoff values to guide therapy.